Social Links

Follow on Facebook Follow on TwitterFollow EiR on PinterestFollow EiR on Instagram

Xpert Access

×

Login To Get Involved!


Forgot your username?


Forgot your password?

×

Join Us At EiR Now!

DNRS Roof Banner

 

DNRS 4th of July Sale! 15% Discount with Code:
DNRSRECOVERY

Universal AJAX Live Search

Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks

IL 13 Attenuates Gastrointestinal Candidiasis

 

 

 

J Immunol. 2008 Apr 1;180(7):4939-4947.

 

IL-13 Attenuates Gastrointestinal Candidiasis in Normal and Immunodeficient RAG-2-/- Mice via Peroxisome Proliferator-Activated Receptor-{gamma} Activation.

 

Coste A, Lagane C, Filipe C, Authier H, Galès A, Bernad J, Douin-Echinard V, Lepert JC, Balard P, Linas MD, Arnal JF, Auwerx J, Pipy B. Laboratoire Polarisation des Macrophages and Récepteurs Nucléaires dans les Pathologies Inflammatoires et Infectieuses, Université Paul Sabatier Toulouse III, Institut National de la Santé et de la Recherche Médicale (INSERM) Institut Fédératif de Recherche (IFR) 31, Institut Louis Bugnard, Toulouse, France;

 

 

We recently demonstrated that in vitro peroxisome proliferator-activated receptor-gamma (PPARgamma) activation of mouse peritoneal macrophages by IL-13 or PPARgamma ligands promotes uptake and killing of Candida albicans through mannose receptor overexpression. In this study, we demonstrate that i.p. treatment of immunocompetent and immunodeficient (RAG-2(-/-)) mice with natural and synthetic PPARgamma-specific ligands or with IL-13 decreases C. albicans colonization of the gastrointestinal (GI) tract 8 days following oral infection with the yeast. We also showed that Candida GI infection triggers macrophage recruitment in cecum mucosa. These mucosal macrophages, as well as peritoneal macrophages, overexpress the mannose receptor after IL-13 and rosiglitazone treatments. The treatments promote macrophage activation against C. albicans as suggested by the increased ability of peritoneal macrophages to phagocyte C. albicans and to produce reactive oxygen intermediates after yeast challenge. These effects on C. albicans GI infection and on macrophage activation are suppressed by treatment of mice with GW9662, a selective PPARgamma antagonist, and are reduced in PPARgamma(+/-) mice. Overall, these data demonstrate that IL-13 or PPARgamma ligands attenuate C. albicans infection of the GI tract through PPARgamma activation and hence suggest that PPARgamma ligands may be of therapeutic value in esophageal and GI candidiasis in immunocompromised patients.

 


 

 

Related Articles:

 

Mold Testing & Sanitizer:

 

 

 

 

ADVERTISEMENT

 

  • No comments found

Leave your comments

Post comment as a guest

0 Character restriction
Your text should be more than 25 characters
Your comments are subjected to administrator's moderation.
terms and condition.

Adsense Responsive BottomBanner